Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Lowsky

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Blood|March 1, 2023
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agentsMichael A Spinner, R A Sica, John S Tamaresis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow TransplantationJeffrey A Cohen, Laura E Baldassari, Harold L Atkins, et al.
Blood Advances|August 25, 2021
Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipientsKent P Jensen, David A Hongo, XuHuai Ji, et al.
Transplantation and Cellular Therapy|January 18, 2022
Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center ReportAndriyana K Bankova, Joseph Caveney, Bin Yao, et al.
Blood Advances|December 13, 2023
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHDCameron S Bader, Anna Pavlova, Robert Lowsky, et al.
Blood Advances|February 11, 2021
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphomaJohn H Baird, David J Epstein, John S Tamaresis, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Blood|January 10, 2025
Donor regulatory T-cell therapy to prevent graft-versus-host diseaseEverett H Meyer, Anna Pavlova, Alejandro Villar-Prados, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Blood|March 1, 2023
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agentsMichael A Spinner, R A Sica, John S Tamaresis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow TransplantationJeffrey A Cohen, Laura E Baldassari, Harold L Atkins, et al.
Blood Advances|August 25, 2021
Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipientsKent P Jensen, David A Hongo, XuHuai Ji, et al.
Transplantation and Cellular Therapy|January 18, 2022
Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center ReportAndriyana K Bankova, Joseph Caveney, Bin Yao, et al.
Blood Advances|December 13, 2023
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHDCameron S Bader, Anna Pavlova, Robert Lowsky, et al.
Blood Advances|February 11, 2021
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphomaJohn H Baird, David J Epstein, John S Tamaresis, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Blood|January 10, 2025
Donor regulatory T-cell therapy to prevent graft-versus-host diseaseEverett H Meyer, Anna Pavlova, Alejandro Villar-Prados, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Pageof 7